Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
BNZ | Ann: NAB 2025 Third Quarter Pillar 3 Report | 18/08/25 | 0 | 58 | |||
|
|||||||
BNZ | Ann: NAB 2025 Third Quarter Trading Update | 18/08/25 | 0 | 51 | |||
|
|||||||
BNZ | Ann: NAB 2025 Half Year Results | 07/05/25 | 0 | 85 | |||
|
|||||||
BNZ | Ann: BNZ Disclosure Statement 31 March 2025 | 07/05/25 | 0 | 107 | |||
|
|||||||
BNZ | Ann: BNZ 2025 Half Year Results Announcement | 07/05/25 | 0 | 88 | |||
|
|||||||
BNZ | Ann: BNZ announces a change to its Board | 17/03/25 | 0 | 93 | |||
|
|||||||
BNZ | Ann: NAB 2025 First Quarter Trading Update | 19/02/25 | 0 | 141 | |||
|
|||||||
BNZ | Ann: NAB 2025 First Quarter Pillar 3 Report | 19/02/25 | 0 | 102 | |||
|
See All Discussions